4/27/2022

speaker
Operator
Conference Operator

Pardon me, this is the operator. Today's conference is scheduled to begin shortly. Please continue to stand by and thank you for your patience. Thank you. Thank you. Ladies and gentlemen, thank you for standing by, and welcome to the Solid Biosciences Strategic Business Update and Financial Results Conference call. At this time, all participants are in a listen-only mode. Please be advised that today's conference may be recorded. After the presentation, there will be a question-and-answer session. To ask a question, please press star 1 on your telephone to get in the queue. I would now like to hand the conference over to Caitlin Lowy, Vice President of Communications and Investor Relations at Solid Biosciences. Ms. Lowy, you may begin.

speaker
Caitlin Lowy
Vice President of Communications and Investor Relations

Good morning. Thank you, Operator. Before we get started, I would like to remind everyone that during today's conference call, we may make forward-looking statements, including statements about the company's financial results, financial guidance, future business strategies and operations, and product development and regulatory progress, including statements about the company's Ignite DMV clinical trial. Actual results could differ material from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, the extent and duration of the impact of the COVID-19 pandemic, and other risks described in the risk factors section of our most recently filed annual report on Form 10-K and other periodic reports filed with the SEC. We undertake no obligation to update any forward-looking statements after the date of this call. With me on today's call are Ilan Ganote, Co-Founder, President, and Chief Executive Officer of Solid Biosciences, Dr. Joel Schneider, our Chief Operating Officer, Dr. Carl Morris, our Chief Scientific Officer, and Dr. Roxana Donisa Dragic, Senior Vice President and Head of Clinical Development. During today's call, we will share details of the strategic update the company announced this morning. We'll begin with opening remarks from Ilan. followed by Joel who will share details of an intended change we'll be making to the manufacturing approach for SGT001. Carl will then review new preclinical data related to SGT003. Finally, Elan will provide an overview of the organizational strategy that aligns behind these two programs before opening the call to questions. Before I turn the call over to Elan, I want to acknowledge that our first quarter financial results have been reported and can also be found on our form 10Q, which was filed with the SEC this morning. For opening remarks, I'd like to turn the call over to CELD's CEO, Ilan Ganot. Ilan?

speaker
Ilan Ganot
Co-Founder, President, and Chief Executive Officer

Thank you, Caitlin, and thanks to all of you for joining us this morning. CELD's ongoing focus on Duchenne has produced two potential therapies for this devastating disease. and to explore the potential benefits of SUT003's novel capsid to deliver our differentiated microdystrophin. This is all supported by a cash position of approximately $180 million at the end of the first quarter of 2022. The Board and SOLID's leadership team remain committed to the progress of both programs, and I'll now summarize our path forward. First, following a thorough assessment currently available alternatives for the manufacturing of STT001, we identified a process that we believe will produce high-quality drug products while narrowing the organization's focus to a single production platform and streamlining our operating structure to a more efficient model. Joel will discuss our revised strategy to advance STT001 into late-stage clinical development with transient transfection-based manufacturing. We believe this transition has minimal impact to our timeline for further development through to the potential BLA filing and improves our potential to make a difference for those living with Duchenne. Second, our next-generation capsules used in STT-Z gene therapy as well as for the broader gene therapy field for muscle disorders. We will continue to advance towards an IND submission in early 2023 and further de-risk this program and the novel Capsid. We expect the clinical proof of concept for HT003 in 2023 will provide further support of our next generation Capsid platform. As a result of the focused approach on these programs and SOLID's CASH runway through Q2 2024, the company will be able to progress through important telephone milestones for both gene therapy programs. I will now hand it over to Joel to go through our SGT001 update in more detail. Thanks, Salon.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-